First-In-Human Phase 1/2a Study of the First-In-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer

By sjmartinez • April 18, 2025

Yap TA, Goldman JW, Vinayak S, Tomova A, Hamilton E, Naito Y, Giordano A, Bondarenko I, Yamashita T, Zhou L, Moreau A, Neumann H, Tougias J, Liu F, Park J, Delioukina M, Jhaveri K. First-In-Human Phase 1/2a Study of the First-In-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer. Clin Cancer Res. 2025 Apr 17. doi: 10.1158/1078-0432.CCR-24-2740. Epub ahead of print. PMID: 40243688.

Tags: Hematology/Oncology, Publications

Oncofertility patterns after the overturn of Roe v. Wade

Baclig NV, Silverstein J, Shah V, Karlan B, Anand SR, Glaspy JA. Oncofertility patterns after the overturn of Roe v. Wade. J Natl Cancer Inst.[...]

Safety First

Moghanaki D, Gower A. Safety First. Int J Radiat Oncol Biol Phys. 2026 May 1;125(1):18. doi: 10.1016/j.ijrobp.2025.12.009. PMID: 42000358.

Personalizing Curative Therapy in Stage II to III Triple-Negative Breast Cancer

LeVee A, Hennessy MA, Idossa D, Leon-Ferre RA, Nanda R, McArthur H. Personalizing Curative Therapy in Stage II to III Triple-Negative Breast Cancer. Am Soc[...]